Travere Therapeutics Hits New 52-Week High of $55.62

Travere Therapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 55.62 on June 18, 2026. This achievement underscores the company's remarkable performance over the past year, with a staggering increase of 658.6%, significantly outpacing the S&P 500's growth of 25.41% during the same period. With a market capitalization of USD 2,514 million, Travere Therapeutics continues to make its mark in the industry despite its current loss-making status, as indicated by its P/E ratio being unavailable. The company's financial metrics reveal a debt-to-equity ratio of -0.05 and a return on equity of -43.77%, reflecting its ongoing efforts to navigate the competitive landscape. Additionally, the stock's price-to-book ratio stands at 21.89, highlighting its valuation relative to its assets. As Travere Therapeutics continues to evolve, this new high serves as a testament to its performance and position within the dynamic pharmaceuticals and biotechnology market.